arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Organon & Co.

OGN
$13.61 ▲ +0.07 (+0.52%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
8 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
56
Health
Fair
Neutral
auto_awesome

Analytical Summary

Organon & Co. shows mixed fundamentals. However, watch Debt to Equity which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $3.5B
Dividend Yield 2.50%
Revenue Growth -2.9%
Op. Margin
ROIC
FCF / Share $2.07
Trailing P/E 18.9x
Price / Book 4.7x
FCF Yield 15.2%
Debt / Equity 11.49
info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.22B
↓ -2.9%
Net Income Profit after all expenses
$187.00M
↓ -78.4%
FCF / Share Free cash flow per share
$2.07
↓ -30.2%
Long-Term Debt Long-term obligations
$8.64B
↓ -2.7%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
49
Returns
90
Financial Health
2
Cash Quality
91

Dividend History

Dividend / share · sourced from SEC filings
$0.34 Latest / share
-69.6% YoY
-11.7% 5-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 28 quarters